Prime Medicine, Inc. Loss Contingency, Receivable
Prime Medicine, Inc. (PRME) had Loss Contingency, Receivable of $13.90 million as of 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LossContingencyReceivable · last filed 2026-03-03
- 2025-09-30: Loss Contingency, Receivable $13.90M.
- 2025-06-30: Loss Contingency, Receivable $13.90M.
- 2025-03-31: Loss Contingency, Receivable $13.90M.
- 2024-12-31: Loss Contingency, Receivable $10.80M.
| Period end | Loss Contingency, Receivable |
|---|---|
| 2025-09-30 | $13.90M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $13.90M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $13.90M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $10.80M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |